Lumen Bioscience's C diff therapy, LMN-201, combines four therapeutic proteins that act synergistically to neutralize both the C difficile bacterium and the toxin that causes its virulence directly in the patient’s gastrointestinal tract.

Inhibiting production of para-cresol could be effective against Clostridioides difficile infection by reducing the pathogen’s ability to compete with other bacteria in the gut microbiome, a new study found.

Commercial kefir was recently found to be effective in curing recurrent Clostridioides difficile infection when consumed alongside antibiotic treatment. However, kefir products have limited acceptance among Western consumers due to their characteristic flavor and texture. Plain, unsweetened commerci …

Microba Life Sciences Ltd. has started dosing patients in a phase I trial of its gut microbiome-derived therapeutic, MAP-315, for ulcerative colitis, the major form of inflammatory bowel disease (IBD).

Luminamicin (b1/b) isolated in 1985, is a macrodiolide compound exhibiting selective antibacterial activity against anaerobes. However, the antibacterial activity of b1/b was not fully examined. In this research, re-evaluation of the antibacterial activity of b1/b revealed that b1/b …

Exeliom Biosciences has completed a €24 million ($26 million) Series A to progress the clinical development of its therapeutic pipeline.

Infection Control Today speaks with the CEO of Blue Water Biotech about how to get around antimicrobial resistance and why there may not be a need for more antibiotic creation.

Acurx develops antibiotic candidates targeting the DNA polymerase IIIC enzyme such as Ibezapolstat, which has received FDA Fast track and QIDP designations to treat #CDiff. The Company also has early stage antibiotics targeting #MRSA, VRE and PRSP. https://t.co/9AArq59ckp $ACXP— Antimicrobials Working Group (@AWG_News) June 22, 2023

Anaerobic microorganisms are often associated with chronic mucosal infections including periodontal disease, inflammatory bowel diseases, and recurrent colitis caused by iClostridioides difficile/i. Management of these diseases requires a long term strategy, but available antibiotics (e.g., metr …

Kim-Lewis-PhD-the-University-Distinguished-Professor-of-Biology-at-Northeastern-University-in-Boston-was-awarded-the-American-Society-for-Microbiology-ASM-

null

Clostridium Difficile Infection Drugs market report has been prepared by considering several fragments of the present and upcoming market scenario The market insights gained through this market research analysis report facilitates more clear understanding of the market landscape issues that ...

University of Notre Dame researchers discovered that an oxadiazole antibiotic—a compound of a previously discovered class that treats MRSA—k...

The COVID-19 pandemic underscored challenges in the prevention and treatment of health care-associated infections.

The report titled Antibiotic Resistance has recently been published by Absolute Markets Insights whi

New process could speed the discovery of other much-needed antibiotics. Scientists at McMaster University and the Massachusetts Institute of Technology have used artificial intelligence to discover a new antibiotic that could be used to fight a deadly, drug-resistant pathogen that strikes vulnerabl

SER-109, also known as fecal microbiota spores, has demonstrated both efficacy and durability for recurrent Clostridioides difficile infection.

Las Vegas Nevada United States As per DelveInsight s assessment globally Clostridium Difficile Infections pipeline constitutes 25 key companies continuously working towards developing 25 Clostridium Difficile Infections treatment therapies analysis of Clinical Trials Therapies Mechanism of Action Route of Administration ...

After a recent $106.5m fundraise, the designation marks another milestone for the company set to start a Phase III study later this year.

The increased research and development activities for developing and launching new drugs are expected to fuel growth in the Clostridium difficile infection...

Previously, 1-((4-(4-bromophenyl)-1H-imidazol-2-yl)methyl)-3-(5-(pyridin-2-ylthio)thiazol-2-yl)urea bearing a p-bromine substitution was shown to possess selective inhibitory activity against the Clostridioides difficile enoyl-acyl carrier protein (ACP) reductase II enzyme, FabK. Inhibition of CdFab …

Previously, 1-((4-(4-bromophenyl)-1H-imidazol-2-yl)methyl)-3-(5-(pyridin-2-ylthio)thiazol-2-yl)urea bearing a p-bromine substitution was shown to possess selective inhibitory activity against the Clostridioides difficile enoyl-acyl carrier protein (ACP) reductase II enzyme, FabK. Inhibition of CdFab …

A novel oral microbial therapy under development by Vedanta Biosciences reduced the risk of recurrence of Clostridioides difficile infection in a phase 2 clinical trial.

Lumen Bioscience Receives Fast Track Designation from U.S. FDA for LMN-201 - read this article along with other careers information, tips and advice on BioSpace

LMN-201, an oral biologic drug developed by Lumen Bioscience, has received Fast Track Designation from the FDA. The drug combines therapeutic proteins to neutralize the bacterium and toxin that cause C difficile infection.

LMN-201 combines 4 therapeutic proteins that act synergistically.